Resultado de búsqueda
El diagnóstico de demencia en enfermedad de Alzheimer aplicando los criterios del DSM-IV apoyados en una historia clínica que incluya un informante confiable y suplementados por una aproximación objetiva mediante tests cognitivos y evaluación neuropsicológica alcanzan un nivel de evidencia tipo II y un grado de recomendación clase B.
2 de ago. de 2019 · Clinical AD dementia cannot be definitively diagnosed until post-mortem neuropathologic evaluation, though research institutes capable of assessing amyloid and tau burden in living patients are challenging this historic paradigm .
All stages of Alzheimer’s disease brain lesions (including amyloid β and tau lesions) are found in two-thirds of individuals aged at least 70 years in systematic post-mortem examination, regardless of clinical status, 17 which far exceeds the expected prevalence (30%) 18 of cognitive impairment
22 de abr. de 2015 · In this review, we discuss the availability of human post-mortem tissue through brain banks, the limitations associated with its use, the technical tools available, and the neuroimmune aspects to explore in order to validate in the human brain the experimental observations arising from animal models.
1 de mar. de 2021 · At post-mortem there are cortical regions that range from mildly to severely affected by tau pathology and neuronal loss. A comparison of the molecular signatures of these differentially...
12 de dic. de 2017 · Markers of microglia in post-mortem brain samples from patients with Alzheimer’s disease: a systematic review. K E Hopperton, D Mohammad, M O Trépanier, V Giuliano & R P Bazinet. Molecular...
24 de jul. de 2020 · PMCID: PMC7463915. DOI: 10.3390/brainsci10080479. Abstract. The definitive diagnosis of Alzheimer's disease (AD) rests with post-mortem neuropathology despite the advent of more sensitive scanning and the search for reliable biomarkers.
